Evidence map›Paper›PMID 38028143›Full record

ArticleTherapeutic advances in medical oncology2023

CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study.

Yuan Yuan, Colt Egelston, Oscar Colunga Flores, Shyambabu Chaurasiya, David Lin, Helen Chang, Leslie Mi Ok Chong, Amanda Seiz, Monil Shah, W Hans Meisen and 12 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors.International journal of molecular sciences · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Yuan YuanCedars-Sinai Medical Center, 127 S San Vicente Blvd, Los Angeles, CA 90048, USA.
Colt EgelstonDepartment of Immune-Oncology, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA.
Oscar Colunga FloresDepartment of Immune-Oncology, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA.
Shyambabu ChaurasiyaDepartment of Surgery, City of Hope Comprehensive Cancer, Duarte, CA, USA.
David LinDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Helen ChangDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Leslie Mi Ok ChongImugene Limited, Sydney, NSW, Australia.
Amanda SeizImugene Limited, Sydney, NSW, Australia.
Monil ShahImugene Limited, Sydney, NSW, Australia.
W Hans MeisenDepartment of Translational Development, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Aileen TangDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Norma MartinezDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Wichanee PickettDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Mireya MurgaDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Susan E YostDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID https://orcid.org/0000-0002-9422-0316
Daphne StewartDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Jianying ZhangDepartment of Statistics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Nicholas EdeImugene Limited, Sydney, NSW, Australia.
Badri ModiDepartment of Surgery, City of Hope Comprehensive Cancer, Duarte, CA, USA.
Jonathan KesslerDepartment of Radiology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Jamie RandDepartment of Surgery, City of Hope Comprehensive Cancer, Duarte, CA, USA.
Yuman FongDepartment of Surgery, City of Hope Comprehensive Cancer, Duarte, CA, USA.ORCID https://orcid.org/0000-0002-8934-9959
City of Hope · USCedars-Sinai Medical Center · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

Prognosis of metastatic triple negative breast cancer (mTNBC) remains poor despite recent advances in therapeutic options. Trastuzumab deruxtecan (T-DXd) has shown promising efficacy in patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer, which is defined by immunohistochemistry (IHC) 1+ or 2+ and lack of HER2 amplification by fluorescence

Indexed as

CF33-hNIS-anti-PD-L1CHECKvaccT-DXdtriple negative breast cancer

Identifiers

PMID38028143
PMCPMC10640805
OpenAlexW4388597801

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.